intradermic needle






















Corona (covid-19) dose sparing

The dose sparing potential of our intradermic vaccination needle Bella-mu 1.4 in combination with any (new) corona vaccine is currently unknown. Although a significant dose sparing potential is expected, it cannot be investigated until a vaccine candidate is available.

Welcome to the intradermic needle company


Clear need for easy-to-use and reliable intradermic needles for injection and infusion

Intradermal injection is emerging as the preferred route of administration for many innovative therapies in therapeutic and prophylactic vaccination, and aesthetics. However, the standard-of-care method for intradermal injection, the almost a century old "Mantoux technique", is a procedure that improperly uses hypodermic needles (intended for injections under the dermis) and as a result is complex and unreliable. Hereby, the Mantoux technique impedes pharmaceutical innovation and there is a clear and urgent need for an easy-to-use but reliable intradermal injection method.

Easy to use

We design and manufacture easy-to-use, patient friendly intradermic needles that are very small (micro), very sharp, highly accurate, reliable and low cost. Our proprietary intradermic needle technology makes use of innovative manufacturing processes and needle designs.

New standard-of-care

Bella-mu is our first registered product range (in EU and US) and well received by clinicians. Learn more about our products here

Carousel imageCarousel imageCarousel image
Carousel imageCarousel imageCarousel image

Dose sparing (up to 10x vaccine dose reduction)

Injection into the skin (dermis) target dendritic cells of the immune system directly and instantly, unlike regular injections in the muscle (IM), where these cells are absent. Vaccine dosing can be reduced by many factors, clinical studies have shown dose sparing potential of factor 3 (Influenza) up to a factor of 10 (Rabies).

Reduced anxiety & pain

Due to the extreme small size and super sharp tip of our microneedles, needle fear and pain are strongly reduced.

Our vision

Microneedle injection technology unlocks the true potential of intradermal drug delivery and become the preferred route of administration for hundreds of existing and future therapies.

More on intradermal administration

Intradermal injection (ID injection) is a shallow or superficial injection of a substance into the dermis part of the skin, in between the epidermis and the hypodermis (or subcutaneous or adipose layer). Due to the complexity of the manoeuvre requiring the use of hypodermic needles today, this route is relatively rare compared to subcutaneous injections (SC) and intramuscular injections(IM), and used only when certain therapies, like tuberculin and allergy tests, require the specific benefits of this route of administration. Specific ID route of administration benefits are a higher immune responses for vaccinations, immunotherapy or novel cancer treatments and a much faster drug uptake. (Small and well soluble proteins or molecules, ID route of administration are taken up much faster systemically compared to SC injections.) Additionally, the body's reaction to substances is more easily visible since it is closer to the surface, which is exploited in allergy testing. Learn more on the human skin.